Landos Biopharma, Inc.
LABPDelisted May 23, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001785345
Landos Biopharma, Inc. was delisted on May 23, 2024; its insiders filed their last Form 4 on May 23, 2024; 16 institutions reported holding it in 13F filings for Q1 2024, worth $34.9M in total; no superinvestor held it.
Q1 2023 vs. Q4 2022
How the institutions holding Landos Biopharma, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 23 | 20 | −3 |
| Shares | 15.7M | 15.5M | −210.8K (−1.3%) |
| Value | $7.87M | $4.63M | −$3.24M (−41.2%) |
New holders (3)
Institutions that held Landos Biopharma, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 86,093 | $25.7K | 0.00% |
| Warberg Asset Management LLC | 73,504 | $21.9K | 0.01% |
| Bank of America Corp | 26 | $8 | 0.00% |
Sold out (6)
Institutions that held Landos Biopharma, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| HRT Financial LP | 52,564 | $26.0K |
| Deutsche Bank AG | 41,760 | $20.9K |
| Jane Street Group, LLC | 14,826 | $7.41K |
| FMR LLC | 2,000 | $1.00K |
| Morgan Stanley | 768 | $384 |
| Citigroup Inc | 519 | $260 |